E-submission
Search
- Page Path
- HOME > Search
Original Article
- The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis
- Alaa Salah Jumaah, Mais Muhammed Salim, Hawraa Sahib Al-Haddad, Katherine Ann McAllister, Akeel Abed Yasseen
- J Pathol Transl Med. 2020;54(6):471-479. Published online September 2, 2020
- DOI: https://doi.org/10.4132/jptm.2020.07.23
- 6,222 View
- 258 Download
- 20 Web of Science
- 22 Crossref
-
Abstract
PDF
Supplementary Material - Background
Endometrial carcinoma (EC) is classified into four distinct molecular subgroups including ultramutated DNA polymerase epsilon (POLE). POLE-mutated tumors have the best prognosis and are a promising target for immunotherapy. This meta-analysis consolidated the reported variation of POLE-mutant frequency and assessed prognostic value in EC.
Methods
Internet searches explored scientific data bases: EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials databases. Data was extracted from eligible studies including: sample size, number of positive POLE-mutant cases, sequencing information, clinicopathologic data, and survival data. Meta-analysis and a random-effects model produced pooled estimates of POLE frequency and prognostic parameters using 95% confidence intervals (CI), hazard ratios (HR), and odd ratios (OR).
Results
Six thousand three hundred and forty-six EC patient cases were pooled from 25 studies. The pooled proportion of POLE gene mutation in EC was 8.59% (95% CI, 7.01 to 10.32), of which 8.22% (95% CI, 6.27 to 10.42) were type I and 0.93% (95% CI, 0.34 to 1.81) type 2. Clinicopathologic data showed that POLE-mutated tumors are mostly endometrioid. They present at higher levels in earlier stages (I–II) of EC (89.51%; 95% CI, 81.11 to 95.66) at the highest grade III (51.53%; 95% CI, 36.08 to 66.84) with reduced myometrial invasion (OR, 1.48, 95% CI, 0.99 to 2.20). Survival analysis indicated favorable overall survival (HR, 0.90), disease-specific survival (HR, 0.41), and progression-free survival (HR, 0.23) for POLE mutant EC.
Conclusions
Almost one-tenth of EC patients have POLE-mutated tumors. Given their improved prognostic potential, identifying the POLE mutation status is key for the management of EC patients. -
Citations
Citations to this article as recorded by
- A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system
Yohei Chiba, Masahiro Kagabu, Mitsumasa Osakabe, Rikako Ito, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Tadahiro Shoji, Naoki Yanagawa, Tsukasa Baba
Japanese Journal of Clinical Oncology.2024; 54(4): 424. CrossRef - Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer
Nuria Agusti, Alexa Kanbergs, Roni Nitecki
Gynecologic Oncology.2024; 185: 121. CrossRef - Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence
Yung-Taek Ouh, Yoonji Oh, Jinwon Joo, Joo Hyun Woo, Hye Jin Han, Hyun Woong Cho, Jae Kwan Lee, Yikyeong Chun, Myoung-nam Lim, Jin Hwa Hong
Cancers.2024; 16(5): 965. CrossRef - The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review
Xiaohong Yao, Min Feng, Wei Wang
Cancer Management and Research.2024; Volume 16: 117. CrossRef - National Survey of Current Follow-up Protocols for Patients Treated for Endometrial Cancer in the UK
H. Patel, K. Drinkwater, A. Stewart
Clinical Oncology.2024;[Epub] CrossRef - Nab-Paclitaxel-Based Systemic Approach to Achieving Complete Remission for Relapsed Stage III Endometrial Carcinoma: Insights From the Indian Subcontinent
Prasanna Rammohan, Vipulkumar Thummar, Priya Mehta
Cureus.2024;[Epub] CrossRef - High prevalence of “non‐pathogenic” POLE mutation with poor prognosis in a cohort of endometrial cancer from South India
Santhosh Kuriakose, Dhananjayan Dhanasooraj, P. M. Shiny, S. Shammy, V. P. Sona, Anupama A. Manjula, Amrutha Ramachandran, Bindu Vijaykumar, Nayana Susan, M. Dinesan, Uma V. Sankar, Kavitha Ramachandran, P. S. Sreedharan
International Journal of Gynecology & Obstetrics.2024;[Epub] CrossRef - Fast and reliable Sanger POLE sequencing protocol in FFPE tissues of endometrial cancer
Izabela Laczmanska, Dagmara Michalowska, Marcin Jedryka, Dorota Blomka, Mariola Semeniuk, Ewelina Czykalko, Mariola Abrahamowska, Paulina Mlynarczykowska, Agnieszka Chrusciel, Ireneusz Pawlak, Adam Maciejczyk
Pathology - Research and Practice.2023; 242: 154315. CrossRef - Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Nadeem Abu-Rustum, Catheryn Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert
Journal of the National Comprehensive Cancer Network.2023; 21(2): 181. CrossRef - The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity
Guillaume Labrousse, Pierre Vande Perre, Genis Parra, Marion Jaffrelot, Laura Leroy, Frederic Chibon, Frederic Escudie, Janick Selves, Jean-Sebastien Hoffmann, Rosine Guimbaud, Malik Lutzmann
NAR Cancer.2023;[Epub] CrossRef - New boundaries for fertility sparing management in endometrial cancer
Alexandros Rodolakis, Vasilis Pergialiotis, Nikolaos Thomakos
Current Opinion in Oncology.2023; 35(5): 394. CrossRef - PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer
New England Journal of Medicine.2023; 389(9): 866. CrossRef - The Shifting Landscape of p53abn Endometrial Cancers: A Review of the Prognostic and Predictive Impact and Current Therapeutic Directions
Angelo Anater
Journal of Medical and Radiation Oncology.2023; 3(2): 1. CrossRef - The Advantages of Next-Generation Sequencing Molecular Classification in Endometrial Cancer Diagnosis
Daniela Rivera, Michele Paudice, Giulia Accorsi, Floriana Valentino, Marta Ingaliso, Ada Pianezzi, Paola Roggieri, Lucia Trevisan, Giulia Buzzatti, Serafina Mammoliti, Fabio Barra, Simone Ferrero, Gabriella Cirmena, Viviana Gismondi, Valerio Gaetano Vello
Journal of Clinical Medicine.2023; 12(23): 7236. CrossRef - CircRNA-miRNA-mRNA interactome analysis in endometrial cancer
Tikam Chand Dakal, Abhishek Kumar, Pawan Kumar Maurya
Journal of Biomolecular Structure and Dynamics.2023; : 1. CrossRef - The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis
Alaa Salah Jumaah, Hawraa Sahib Al-Haddad, Katherine Ann McAllister, Akeel Abed Yasseen, Manish S. Patankar
PLOS ONE.2022; 17(2): e0263585. CrossRef - Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ϵ variants at low dNTP levels
Stephanie R Barbari, Annette K Beach, Joel G Markgren, Vimal Parkash, Elizabeth A Moore, Erik Johansson, Polina V Shcherbakova
Nucleic Acids Research.2022; 50(14): 8023. CrossRef - The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review
Amelia Favier, Justine Varinot, Catherine Uzan, Alex Duval, Isabelle Brocheriou, Geoffroy Canlorbe
Cancers.2022; 14(15): 3783. CrossRef - The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients
Qing Wu, Nianhai Zhang, Xianhe Xie
BMC Cancer.2022;[Epub] CrossRef - Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis
Alaa Salah Jumaah, Hawraa Sahib Al-Haddad, Mais Muhammed Salem, Katherine Ann McAllister, Akeel Abed Yasseen
Journal of Pathology and Translational Medicine.2021; 55(3): 202. CrossRef - Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessand
Cancer.2021; 127(14): 2409. CrossRef - Endometrial cancer
Vicky Makker, Helen MacKay, Isabelle Ray-Coquard, Douglas A. Levine, Shannon N. Westin, Daisuke Aoki, Ana Oaknin
Nature Reviews Disease Primers.2021;[Epub] CrossRef
- A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system
First
Prev
